HPV Vaccine Impact Evaluation Study
Impact of 2-dose and1-dose human papillomavirus (HPV) vaccination schedules on community level HPV prevalence in South African adolescent girls
Primary Objectives
Primary Objectives In South African adolescent girls aged 17–18 years; • To measure the population effectiveness of the national 2-dose vaccine schedule, delivered at age 9 years, in protecting against infection with sexually transmitted HPV16 and 18; • To measure the population effectiveness of a 1-dose vaccine schedule, delivered via a demonstration project to girls in Grade 10 of public school, in protecting against infection with sexually transmitted HPV16 and 18; and • To determine whether HIV infection status affects the protective effectiveness of HPV vaccines
Study population
For the single dose catch-up, all Grade 10 girls in Free State will be eligible for vaccination For the HPV prevalence surveys. adolesecent girls aged 17-18 years would be surveyed in 2019, 2021, and 2023
Investigator
- Prof. Sinead Delany-Moretlwe : Principal Investigator
Protocol Team
- Prof. Helen Rees: Co-Investigator
- Dr. Admire Chkandiwa: Co-Investigator
Sponsors/Donors
- Bill and Melinda Gates Foundation
- Australian National Health Research Medical Council
Latest Update:
15 February 2021
For more about HPV Vaccine Impact Evaluation Study please email rhicomms@wrhi.ac.za
